NASDAQ:BIOCBiocept Stock Price, Forecast & News

Biocept's stock was trading at $0.3769 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BIOC shares have increased by 69.5% and is now trading at $0.6388. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biocept.

Biocept is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Biocept.

Biocept Inc (NASDAQ:BIOC) posted its earnings results on Wednesday, May, 13th. The medical research company reported ($0.08) earnings per share for the quarter. The medical research company earned $1.45 million during the quarter. Biocept had a negative return on equity of 185.80% and a negative net margin of 463.52%. View Biocept's earnings history.

2 analysts have issued 1-year target prices for Biocept's shares. Their forecasts range from $1.00 to $1.00. On average, they expect Biocept's share price to reach $1.00 in the next year. This suggests a possible upside of 56.5% from the stock's current price. View analysts' price targets for Biocept.

Headlines about BIOC stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biocept earned a news impact score of -2.1 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Biocept.

Some companies that are related to Biocept include DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Anpac Bio-Medical Science (ANPC), Miragen Therapeutics (MGEN), Psychemedics (PMD), OpGen (OPGN), Avant Diagnostics (AVDX), CBA Florida (CBAI), PotNetwork (POTN), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include Walmart (WMT), AVEO Pharmaceuticals (AVEO), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Advanced Micro Devices (AMD), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), T2 Biosystems (TTOO) and VBI Vaccines (VBIV).

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BIOC stock can currently be purchased for approximately $0.64.

Biocept has a market capitalization of $83.75 million and generates $5.53 million in revenue each year. The medical research company earns $-25,140,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. Biocept employs 95 workers across the globe.

The official website for Biocept is www.biocept.com.

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]